Literature DB >> 9694549

Direct vascular effects of HMG-CoA reductase inhibitors.

S Bellosta1, F Bernini, N Ferri, P Quarato, M Canavesi, L Arnaboldi, R Fumagalli, R Paoletti, A Corsini.   

Abstract

Several studies have demonstrated that any beneficial effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events are linked to their hypocholesterolemic properties. However, since mevalonic acid (MVA), the product of the enzyme reaction, is the precursor of numerous metabolites, inhibition of HMG-CoA reductase has the potential to result in pleiotropic effects. MVA and other intermediates of cholesterol synthesis (isoprenoids) are necessary for cell proliferation and other important cell functions, hence effects other than cholesterol reduction may help to explain the antiatherosclerotic properties of statins. Recently, we provided in vitro evidence that fluvastatin, simvastatin, lovastatin, cerivastatin, but not pravastatin, dose-dependently decrease smooth muscle cells (SMC) migration and proliferation, independently of their ability to reduce plasma cholesterol. Moreover, statins are able to reduce the in vitro cholesterol accumulation in macrophages, by blocking cholesterol esterification and endocytosis of modified lipoproteins. This in vitro inhibition was completely prevented by the addition of mevalonate and partially by all-trans farnesol and all-trans geranylgeraniol, confirming the specific role of isoprenoid metabolites--probably through a prenylated protein(s)--in regulating these cellular events. The inhibitory effect of lipophilic statins on SMC proliferation has been recently shown in different models of proliferating cells such as cultured arterial myocytes and rapidly proliferating carotid and femoral intimal lesions in rabbits. Finally, ex vivo studies recently showed that sera from fluvastatin-treated patients interfere with smooth muscle cell proliferation. These results suggest that HMG-CoA reductase inhibitors exert a direct antiatherosclerotic effect in the arterial wall, beyond their effects on plasma lipids, that could translate into a more significant prevention of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694549     DOI: 10.1016/s0021-9150(97)00319-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  33 in total

1.  HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins.

Authors:  Franz Wiesbauer; Christoph Kaun; Gerlinde Zorn; Gerald Maurer; Kurt Huber; Johann Wojta
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

Authors:  G Martin; H Duez; C Blanquart; V Berezowski; P Poulain; J C Fruchart; J Najib-Fruchart; C Glineur; B Staels
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 3.  Comparing HMG-CoA reductase inhibitors.

Authors:  Peter H Jones
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

Review 4.  [Non-lipid effects of statins: myth or fact?].

Authors:  Eleonora Urbauer; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2003

5.  Statin therapy is not associated with improved vascular access outcomes.

Authors:  Roberto Pisoni; Jill Barker-Finkel; Michael Allo
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

6.  Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia.

Authors:  Anna Tavridou; Apostolos Efthimiadis; Ioannis Efthimiadis; Vangelis G Manolopoulos
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

7.  Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis.

Authors:  Xiaobei Wang; Zhenshan Jia; Yosif Almoshari; Subodh M Lele; Richard A Reinhardt; Dong Wang
Journal:  Pharm Res       Date:  2018-06-25       Impact factor: 4.200

Review 8.  [Therapy with CSE inhibitors--more than lipid lowering?].

Authors:  A Weizel
Journal:  Herz       Date:  1999-02       Impact factor: 1.443

Review 9.  Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia.

Authors:  Stefan John; Roland E Schmieder
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

10.  Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation.

Authors:  F Fischetti; R Carretta; G Borotto; P Durigutto; R Bulla; P L Meroni; F Tedesco
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.